Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRSN Neurosense Therapeutics Ltd

Pre-Market Trading 12-24 08:01:26 EST

1.25

-0.11

-8.09%

盘前1.27

+0.02+1.68%

08:00 EST

High1.28	Low0.9600	Vol1.45M
Open1.20	D1 Closing1.36	Amplitude23.53%
Mkt Cap28.91M	Tradable Cap16.96M	Total Shares23.13M
T/O1.66M	T/O Rate10.69%	Tradable Shares13.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NRSN","market":"US","secType":"STK","nameCN":"Neurosense Therapeutics Ltd","latestPrice":1.25,"timestamp":1734987600000,"preClose":1.36,"halted":0,"volume":1450549,"hourTrading":{"tag":"盘前","latestPrice":1.271,"preClose":1.25,"latestTime":"08:00 EST","volume":639,"amount":790.2100206,"timestamp":1735045200775},"delay":0,"floatShares":13567500,"shares":23126000,"eps":-0.66334,"marketStatus":"Pre-Market Trading","change":-0.11,"latestTime":"12-24 08:01:26 EST","open":1.2,"high":1.28,"low":0.96,"amount":1663178.0152748001,"amplitude":0.235294,"askPrice":1.31,"askSize":153,"bidPrice":1.19,"bidSize":165,"shortable":0,"etf":0,"ttmEps":-0.66334,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1735050600000},"marketStatusCode":1,"adr":0,"listingDate":1639026000000,"exchange":"NASDAQ","adjPreClose":1.25,"preHourTrading":{"tag":"盘前","latestPrice":1.271,"preClose":1.25,"latestTime":"08:00 EST","volume":639,"amount":790.2100206,"timestamp":1735045200775},"postHourTrading":{"tag":"盘后","latestPrice":1.29,"preClose":1.25,"latestTime":"19:57 EST","volume":2602,"amount":3297.4028,"timestamp":1735001856748},"volumeRatio":1.6014014078539618},"requestUrl":"/m/hq/s/NRSN","defaultTab":"news","newsList":[{"id":"2493766371","title":"NeuroSense Signs Term Sheet for Phase 3 PrimeC Trial in Amyotrophic Lateral Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2493766371","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493766371?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:44","pubTimestamp":1734965048,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics  said Monday it has signed a binding term sheet with an unnamed pharmaceutical company to further develop PrimeC as potential treatment for amyotrophic lateral sclerosis in some key markets.NeuroSense said it would keep full rights to PrimeC in other key territories.The term sheet includes a \"substantial\" upfront payment\" and funding for a phase 3 study as well as milestone payments and royalties on annual net sales, NeuroSense said.A definitive agreement is expected to be finalized in Q1 2025, the company added.NeuroSense's shares were down more than 16% in early trading Monday.Price: 1.13, Change: -0.23, Percent Change: -16.91","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2493632627","title":"NeuroSense enters binding term sheet to advance PrimeC for ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2493632627","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493632627?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:05","pubTimestamp":1734962721,"startTime":"0","endTime":"0","summary":"NeuroSense (NRSN) Therapeutics announced that it has entered into a binding term sheet with a leading global pharmaceutical company to advance the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-enters-binding-term-sheet-to-advance-primec-for-als?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-enters-binding-term-sheet-to-advance-primec-for-als?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2493768477","title":"Neurosense Therapeutics Enters Binding Term Sheet to Advance Primec for ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2493768477","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493768477?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:00","pubTimestamp":1734962437,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NO0A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2493684447","title":"Neurosense Therapeutics Ltd: Co Would Retain Full Rights to Primec in Other Key Territories","url":"https://stock-news.laohu8.com/highlight/detail?id=2493684447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493684447?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:00","pubTimestamp":1734962437,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NO0A6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2493768260","title":"Press Release: NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2493768260","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493768260?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:00","pubTimestamp":1734962400,"startTime":"0","endTime":"0","summary":"-- Binding Term Sheet with a leading global pharmaceutical company includes. a substantial upfront payment and funding for the Phase 3 study. -- Additionally, milestone payments and double-digit royalties on annual net. -- The transaction is subject to finalization of a definitive agreement,CAMBRIDGE, Mass., Dec. 23, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  , a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announced today that it has entered into a binding term sheet with a leading global pharmaceutical company to advance the development and commercialization of PrimeC, its proprietary treatment drug for amyotrophic lateral sclerosis  in certain key territories. NeuroSense would retain full rights to PrimeC in other key territories.The binding term sheet outlines substantial financial terms from the pharmaceutical company, including:. During the first 6 months of the trial, 45 participants were randomized to r","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN","LENZ"],"gpt_icon":0},{"id":"2492139238","title":"Neurosense Therapeutics Ltd reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2492139238","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492139238?lang=en_us&edition=fundamental","pubTime":"2024-12-19 01:28","pubTimestamp":1734542887,"startTime":"0","endTime":"0","summary":"Neurosense Therapeutics Ltd reports results for the quarter ended September 30 - Earnings SummaryNeurosense Therapeutics Ltd NRSN.OQ reported a quarterly adjusted loss of 11 cents per share for the qu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nL8N3NJ1EX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN"],"gpt_icon":0},{"id":"2492180810","title":"NeuroSense Therapeutics 9-Month EPS $(0.48) Up From $(0.55) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2492180810","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492180810?lang=en_us&edition=fundamental","pubTime":"2024-12-18 23:35","pubTimestamp":1734536106,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics 9-Month EPS $(0.48) Up From $(0.55) YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/12/42556516/neurosense-therapeutics-9-month-eps-0-48-up-from-0-55-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","LENZ"],"gpt_icon":0},{"id":"2492187164","title":"Neurosense Therapeutics 9M EPS USD -0.48","url":"https://stock-news.laohu8.com/highlight/detail?id=2492187164","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492187164?lang=en_us&edition=fundamental","pubTime":"2024-12-18 23:26","pubTimestamp":1734535561,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nPLX6B41D9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2492187131","title":"Press Release: NeuroSense Provides Business Update and Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2492187131","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492187131?lang=en_us&edition=fundamental","pubTime":"2024-12-18 23:26","pubTimestamp":1734535560,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  , a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided business update with corporate highlights to date and third quarter financial results.\"The completion of the 18-month Phase 2b PARADIGM study was a major milestone for NeuroSense. The results highlight PrimeC's potential impact on slowing disease progression and survival benefits in people living with ALS. Furthermore, the positive feedback from a Type C meeting with the FDA on the pivotal study design has the Company on track to commence a Phase 3 study in mid-2025. In parallel, the Company is taking steps toward early commercialization in Canada, with an anticipated potential launch in 2026, bringing us closer to delivering a much-needed solution to the ALS community,\" stated Alon Ben-Noon, CEO of NeuroSense.In December 2024, NeuroSense announced a $5 million private placement at p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2491693785","title":"Neurosense Therapeutics Ltd : Maxim Group Cuts to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2491693785","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491693785?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:05","pubTimestamp":1734354336,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nFWN3NH117:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2491069386","title":"NeuroSense downgraded to Hold from Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2491069386","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491069386?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:41","pubTimestamp":1734352865,"startTime":"0","endTime":"0","summary":"Maxim downgraded NeuroSense (NRSN) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-downgraded-to-hold-from-buy-at-maxim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-downgraded-to-hold-from-buy-at-maxim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2490863748","title":"NeuroSense concludes Type C meeting with FDA for PrimeC treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2490863748","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490863748?lang=en_us&edition=fundamental","pubTime":"2024-12-11 22:30","pubTimestamp":1733927418,"startTime":"0","endTime":"0","summary":"NeuroSense (NRSN) Therapeutics announced it has concluded a Type C meeting with the FDA for PrimeC in the treatment of amyotrophic lateral sclerosi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-concludes-type-c-meeting-with-fda-for-primec-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-concludes-type-c-meeting-with-fda-for-primec-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2490558868","title":"BRIEF-Neurosense Receives Positive FDA Feedback On Phase 3 Study Design For Primec","url":"https://stock-news.laohu8.com/highlight/detail?id=2490558868","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490558868?lang=en_us&edition=fundamental","pubTime":"2024-12-11 22:29","pubTimestamp":1733927362,"startTime":"0","endTime":"0","summary":"BRIEF-Neurosense Receives Positive FDA Feedback On Phase 3 Study Design For PrimecDec 11 (Reuters) - Neurosense Therapeutics NRSN.O:NEUROSENSE RECEIVES POSITIVE FDA FEEDBACK ON PHASE 3 STUDY DESIGN FO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nFWN3NC0NQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2490850098","title":"Neurosense Receives Positive FDA Feedback on Phase 3 Study Design for Primec","url":"https://stock-news.laohu8.com/highlight/detail?id=2490850098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490850098?lang=en_us&edition=fundamental","pubTime":"2024-12-11 22:25","pubTimestamp":1733927107,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nFWN3NC0NQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2490850061","title":"Neurosense Therapeutics Ltd: Plans to Submit Final Protocol to FDA During First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2490850061","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490850061?lang=en_us&edition=fundamental","pubTime":"2024-12-11 22:25","pubTimestamp":1733927107,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nFWN3NC0NQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2490868310","title":"NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC","url":"https://stock-news.laohu8.com/highlight/detail?id=2490868310","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490868310?lang=en_us&edition=fundamental","pubTime":"2024-12-11 22:25","pubTimestamp":1733927100,"startTime":"0","endTime":"0","summary":"The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025. PrimeC has already demonstrated a significant impact on slowing disease progression and increasing survival rates in people living with ALS. Amyotrophic lateral sclerosis  is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of$1 billion. The number of people living with ALS is expected to g","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/t.bx.Ue6Dj8iT36MWBDTYw--~B/aD0xNjA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/488fd1dd822c4adae2c61a5f94250e7d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/t.bx.Ue6Dj8iT36MWBDTYw--~B/aD0xNjA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/488fd1dd822c4adae2c61a5f94250e7d"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurosense-receives-positive-fda-feedback-142500846.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurosense-receives-positive-fda-feedback-142500846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHH","WRD","NRSNW","BK4139","NRSN"],"gpt_icon":0},{"id":"2490088919","title":"Rimon Gold Assets Ltd. Reports  9.99% Passive Stake in Neurosense Therapeutics Ltd as of Dec 2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2490088919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490088919?lang=en_us&edition=fundamental","pubTime":"2024-12-10 05:02","pubTimestamp":1733778142,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nFWN3NA1CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2489262894","title":"NeuroSense Therapeutics Files Prospectus for Secondary Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2489262894","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489262894?lang=en_us&edition=fundamental","pubTime":"2024-12-07 06:03","pubTimestamp":1733522630,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics (NRSN) late Friday disclosed plans by one of its larger institutional investors to sell a portion of its stake in the biotechnology company from time to time.The company filed ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","NRSN"],"gpt_icon":0},{"id":"2488519905","title":"NeuroSense’s PrimeC Shows Promise in ALS Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2488519905","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488519905?lang=en_us&edition=fundamental","pubTime":"2024-12-04 21:58","pubTimestamp":1733320710,"startTime":"0","endTime":"0","summary":"Neurosense Therapeutics Ltd. (NRSN) has released an update. NeuroSense Therapeutics has announced promising results from its PARADIGM study, showin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurosenses-primec-shows-promise-in-als-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurosenses-primec-shows-promise-in-als-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2488199700","title":"NeuroSense announces ‘positive’ results from the PARADIGM study","url":"https://stock-news.laohu8.com/highlight/detail?id=2488199700","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488199700?lang=en_us&edition=fundamental","pubTime":"2024-12-04 21:41","pubTimestamp":1733319690,"startTime":"0","endTime":"0","summary":"NeuroSense (NRSN) Therapeutics is pleased to announce statistically significant positive results from the 18-month data analysis of the PARADIGM st...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-announces-positive-results-from-the-paradigm-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-announces-positive-results-from-the-paradigm-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurosense-tx.com","stockEarnings":[{"period":"1week","weight":0.4145},{"period":"1month","weight":0.3889},{"period":"3month","weight":0},{"period":"6month","weight":0.4678},{"period":"1year","weight":0.6114},{"period":"ytd","weight":0.5924}],"compareEarnings":[{"period":"1week","weight":-0.0199},{"period":"1month","weight":-0.0014},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2555},{"period":"ytd","weight":0.2512}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.221221},{"month":2,"riseRate":1,"avgChangeRate":0.311932},{"month":3,"riseRate":0.666667,"avgChangeRate":0.159968},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.220216},{"month":5,"riseRate":0,"avgChangeRate":-0.196146},{"month":6,"riseRate":0.666667,"avgChangeRate":0.463109},{"month":7,"riseRate":0,"avgChangeRate":-0.298623},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.020927},{"month":9,"riseRate":0.333333,"avgChangeRate":0.033411},{"month":10,"riseRate":0,"avgChangeRate":-0.15772},{"month":11,"riseRate":0.666667,"avgChangeRate":0.553258},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.135597}],"exchange":"NASDAQ","name":"Neurosense Therapeutics Ltd","nameEN":"Neurosense Therapeutics Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Neurosense Therapeutics Ltd,NRSN,Neurosense Therapeutics Ltd股票,Neurosense Therapeutics Ltd股票老虎,Neurosense Therapeutics Ltd股票老虎国际,Neurosense Therapeutics Ltd行情,Neurosense Therapeutics Ltd股票行情,Neurosense Therapeutics Ltd股价,Neurosense Therapeutics Ltd股市,Neurosense Therapeutics Ltd股票价格,Neurosense Therapeutics Ltd股票交易,Neurosense Therapeutics Ltd股票购买,Neurosense Therapeutics Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction